|
|
Registered User
Currently Offline
|
Posts: 1
Join Date: Jan 2012
|
|
Coronary artery disease is the major cause of death in the developed <STRONG><EM><U><A href="http://www.selleckchem.com/screening-libraries.html" target=_blank><STRONG><EM><U>High Throughput Screening</U></EM></STRONG></A></U></EM></STRONG> and an emerging health problem in developing countries. Ischaemic heart disease causes millions of deaths worldwide and remains the leading cause of <STRONG><U><EM><A href="http://www.selleckchem.com/screening-libraries.html" target=_blank><STRONG><U><EM>Screening Libraries</EM></U></STRONG></A></EM></U></STRONG> and mortality in the developed world. There have been major advances in preventing and treating atherosclerotic vascular <STRONG><EM><U><A href="http://www.selleckchem.com/screening-libraries.html" target=_blank><STRONG><EM><U>Screening Library</U></EM></STRONG></A></U></EM></STRONG>. However, many patients with ischemic coronary artery disease suffer from disabling symptoms despite intense <STRONG><EM><U><A href="http://www.selleckchem.com/screening-libraries.html" target=_blank><STRONG><EM><U>Compound Libraries</U></EM></STRONG></A></U></EM></STRONG> and are not eligible for invasive revascularization by angioplasty or <STRONG><U><EM><A href="http://www.selleckchem.com/screening-libraries.html" target=_blank><STRONG><U><EM>compound library</EM></U></STRONG></A></EM></U></STRONG>.In such patients the challenge to improve blood flow to the ischemic heart has led to extensive research programs and numerous innovative approaches in the fields of molecular <STRONG><U><EM><A href="http://www.selleckchem.com/screening-libraries.html" target=_blank><STRONG><U><EM>Chemical Libraries</EM></U></STRONG></A></EM></U></STRONG>, pharmacotherapy and newer mechanical technologies. These approaches include promoting the growth of new blood vessels in the <STRONG><U><EM><A href="http://www.selleckchem.com/" target=_blank><STRONG><U><EM>kinase inhibitor</EM></U></STRONG></A></EM></U></STRONG> using several potential compounds, delivery vectors, and delivery mechanisms to the ischemic myocardium. Studies, both in human and <STRONG><U><EM><A href="http://www.selleckchem.com/" target=_blank><STRONG><U><EM>kinase inhibitors</EM></U></STRONG></A></EM></U></STRONG> support the notion that various angiogenic growth factors and progenitor cells can enhance formation of new blood vessels. Progress in understanding the <STRONG><EM><U><A href="http://www.selleckchem.com/pathways_PARP.html" target=_blank><STRONG><EM><U>parp inhibitor</U></EM></STRONG></A></U></EM></STRONG> of angiogenesis, the isolation of angiogenic growth factors, successful preclinical studies, and <STRONG><EM><U><A href="http://www.selleckchem.com/pathways_PARP.html" target=_blank><STRONG><EM><U>parp inhibitors</U></EM></STRONG></A></U></EM></STRONG> early clinical trials have created great excitement about the potential of therapeutic angiogenesis.<BR> The field of angiogenesis research was established almost 30 years ago by the Folkman hypothesis that tumor growth is <STRONG><EM><U><A href="http://www.selleckchem.com/products/PLX-4032.html" target=_blank><STRONG><EM><U>PLX-4032</U></EM></STRONG></A></U></EM></STRONG>. In the early 1970s, it became possible to culture vascular endothelial cells in vitro for the first time. <STRONG><EM><U><A href="http://www.selleckchem.com/products/PLX-4032.html" target=_blank><STRONG><EM><U>Vemurafenib</U></EM></STRONG></A></U></EM></STRONG> for angiogenesis were developed subsequently throughout that decade. The early 1980s saw the purification of the first angiogenic factors. The <STRONG><EM><U><A href="http://www.selleckchem.com/products/PLX-4032.html" target=_blank><STRONG><EM><U>Zelboraf</U></EM></STRONG></A></U></EM></STRONG> of the coronary collateral circulation has become increasingly clear over the past 20 years. Following experimental proof of <STRONG><U><EM><A href="http://www.selleckchem.com/products/PF-2341066.html" target=_blank><STRONG><U><EM>Crizotinib</EM></U></STRONG></A></EM></U></STRONG>, the first promising results of therapeutic angiogenesis in humans were reported in severely symptomatic patients with critical limb <STRONG><EM><U><A href="http://www.selleckchem.com/products/PF-2341066.html" target=_blank><STRONG><EM><U>PF-2341066</U></EM></STRONG></A></U></EM></STRONG>.
|
